Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $6.00 price objective on the stock. Separately, Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies […]
Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $6.00 price objective on the stock. Separately, Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies […]